Multidrug Resistant Tuberculosis Clinical Trial
— TB-TRUSTplusOfficial title:
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (TB-TRUST)-PLUS
Verified date | April 2023 |
Source | Huashan Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA sensitivity for 24 to 36 weeks in subjects with fluoroquinolone-resistant MDR-TB .
Status | Active, not recruiting |
Enrollment | 89 |
Est. completion date | November 30, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Willing to participate in trial treatment and follow-up and can give informed consent - 18-70 years old - Has smear-positive pulmonary tuberculosis with initial laboratory results with resistance to rifampicin and isoniazide confirmed by GeneXpert - documented resistance to fluoroquinolones at screening - Can use bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide drugs concerning the availability and costs of essential medicines - Willing to carry out HIV testing. - If the patient is a non-menopausal woman, agree to use or have used effective contraception during treatment. - Have an identifiable address and stay in the area during the study period. - Willing to follow the follow-up study procedure after the follow-up. Exclusion Criteria: - Combined extrapulmonary tuberculosis; - HIV antibody positive and AIDS patients; - Critically ill patients, and according to the judgment of the research physician, it is impossible to survive for more than 16 weeks; - Known to be pregnant or breastfeeding; - Unable to attend or follow treatment or follow-up time; - Can not take oral medications; - Patients with impaired liver function (hepatic encephalopathy, ascites; total bilirubin is more than 2 times higher than the upper limit of normal; ALT or AST is more than 5 times the upper limit of normal); - Blood muscle spasm is more than 1.5 times the upper limit of normal; - The investigator believes that there are any social or medical conditions that expose the subject to a safety hazard; - Simultaneously apply the drugs (glucocorticoids, interferons) that affect the efficacy of this study; and apply the following drugs contraindicated with the study drug, including non-steroidal anti-inflammatory drugs, monoamine oxidase inhibitors (phenethyl hydrazine, different Carbofurs et al), direct or indirect sympathomimetic drugs (such as pseudoephedrine), vasopressor drugs (such as adrenaline, norepinephrine), dopamine drugs (such as dopamine, dobutamine), 5 a serotonin reuptake inhibitor, a tricyclic antidepressant, a serotonin 5-HTI receptor antagonist (amitriptyline), meperidine or buspirone. - Being allergic or intolerant of any study drug; - Currently participating in another drug clinical trial; - QTc interval = 500 milliseconds during screening; - Hemoglobin is less than 90g/L or platelet is less than 75*10^9/L; - Have epilepsy, severe depression, irritability or psychosis; - Alcohol abuse(drinking more than 64g of ethanol a day for male, 42g for female). - Subjects receive more than 2 weeks of bedaquiline, linezolid, cycloserine, clofazimine or pyrazinamide 3 months prior to enrolment. |
Country | Name | City | State |
---|---|---|---|
China | Baoshan People's Hospital | Baoshan | Yunnan |
China | Hunan Chest Hospital | Changsha | Hunan |
China | Guiyang Public Health Treatment Center | Guizhou | Guizhou |
China | Hangzhou Red Cross Hospital | Hangzhou | Zhejiang |
China | Huaihua first people's Hospital | Huaihua | Hunan |
China | Yunnan Provincial Infectious Disease Hospital | Kunming | Yunnan |
China | Jiangxi Chest Hospital | Nanchang | |
China | Hwa Mei Hosptal,University of Chinese Academy of Sciences(Ningbo No.2 Hospital) | Ningbo | Zhejiang |
China | Huashan Hospital of Fudan University | Shanghai | Shanghai |
China | The Third People's Hospital of Shenzhen City | Shenzhen | Guangzhou |
China | Taizhou Enze medical center Enze Hospital | Taizhou | Zhejiang |
China | Chest Hospitalof Xinjiang Uygur Autonomous Region of PRC | Urumqi | Xinjiang |
China | The Central Hospital of Wenzhou City | Wenzhou | Zhejiang |
China | Shanxi Provincial Tuberculosis Control Institute | Xi'an | Shanxi |
China | The Sixth People's Hospital of Zhengzhou | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Huashan Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment success rate | To access the treatment success rate without relapse .Treatment outcomes will be classified into favourable outcome and unfavourable outcome. | 84 weeks after the treatment initiation | |
Secondary | The median time to Sputum Culture Conversion | time from treatment initiation to the first of two consecutive negative sputum cultures without an intervening positive culture in liquid media | Time Frame: 12-36 weeks after treatment initiation | |
Secondary | The frequency of grade 3 or greater adverse events among patients | to access the proportion of patients who experience grade 3 or greater adverse events (graded according to the Division of AIDS severity criteria for adverse events) during treatment or follow-up; | 84 weeks after treatment initiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05017324 -
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
|
N/A | |
Active, not recruiting |
NCT02496572 -
Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
|
Phase 3 | |
Completed |
NCT03942354 -
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
|
||
Completed |
NCT02454205 -
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05081401 -
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
|
||
Completed |
NCT01856634 -
Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
|
Phase 1 | |
Active, not recruiting |
NCT03867136 -
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
|
Phase 4 | |
Not yet recruiting |
NCT04484129 -
MDR-TB Close Contacts Tracing in China (TCCT Study)
|
||
Completed |
NCT00727844 -
Linezolid to Treat Extensively-Drug Resistant Tuberculosis
|
Phase 2 | |
Completed |
NCT01859923 -
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
|
Phase 2 | |
Active, not recruiting |
NCT04421495 -
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
|
Phase 4 | |
Not yet recruiting |
NCT03604848 -
NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB
|
N/A | |
Recruiting |
NCT02120638 -
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
|
Phase 3 | |
Recruiting |
NCT05534750 -
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
|
Phase 2 |